Anavex Life Sciences | 10-Q: Q3 2024 Earnings Report
Anavex Life Sciences | 8-K: Current report
Anavex Life Sciences | S-3: Registration statement for specified transactions by certain issuers
Anavex Life Sciences | 8-K: Current report
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Donhauser Peter D.O.
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Thomas Steffen
Anavex Life Sciences | 10-Q: Q2 2024 Earnings Report
Anavex Life Sciences | 8-K: Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences | DEF 14A: Definitive information statements
Anavex Life Sciences | DEFA14A: Others
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Officer MISSLING CHRISTOPHER U
Anavex Life Sciences | 144: Notice of proposed sale of securities pursuant to Rule 144
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Skarpelos Athanasios
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Ma Jiong
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Velden Claus Vander
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Thomas Steffen
Anavex Life Sciences | 4: Statement of changes in beneficial ownership of securities-Director Donhauser Peter D.O.
Anavex Life Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.31%)
Anavex Life Sciences | 10-Q: Q1 2024 Earnings Report
Anavex Life Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(8.1%)